Sigyn Therapeutics (SIGY) Total Non-Current Liabilities (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Total Non-Current Liabilities of $2.1 million for Q3 2025, up 5401.96% sequentially from $37501.0 in Q1 2025, and up 2660.33% YoY from $74748.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $2.1 million in Q3 2025.
- Quarterly Total Non-Current Liabilities rose 2660.33% year-over-year to $2.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $2.1 million (up 2660.33% YoY) and the FY2024 annual result came in at $56356.0, down 55.38% from the prior year.
- Total Non-Current Liabilities climbed to $2.1 million in Q3 2025 per SIGY's latest filing, from $37501.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $2.1 million in Q3 2025 and troughed at $37501.0 in Q1 2025.
- A 5-year average of $271858.6 and a median of $173037.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2025: Total Non-Current Liabilities sank 92.63% in 2021, then soared 2660.33% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $240625.0 in 2021, then declined by 22.11% to $187425.0 in 2022, then slumped by 32.61% to $126302.0 in 2023, then tumbled by 55.38% to $56356.0 in 2024, then surged by 3561.17% to $2.1 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.1 million, $37501.0, and $56356.0 for Q3 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 9.32 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 2.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 37,501.00 |
| Dec 31, 2024 | 56,356.00 |
| Sep 30, 2024 | 74,748.00 |
| Jun 30, 2024 | 92,689.00 |
| Mar 31, 2024 | 109,801.00 |
| Dec 31, 2023 | 126,302.00 |
| Sep 30, 2023 | 142,398.00 |
| Jun 30, 2023 | 158,098.00 |
| Mar 31, 2023 | 173,037.00 |
| Dec 31, 2022 | 187,425.00 |
| Sep 30, 2022 | 201,457.00 |
| Jun 30, 2022 | 215,146.00 |
| Mar 31, 2022 | 228,135.00 |
| Dec 31, 2021 | 240,625.00 |
| Sep 30, 2021 | 252,807.00 |
| Jun 30, 2021 | 261,782.00 |
| Sep 30, 2020 | 3.43 Mn |
| Jun 30, 2020 | 3.29 Mn |
| Mar 31, 2020 | 3.20 Mn |